Advertisement

Clinical and Cost Effectiveness of Neuromodulation Devices in the Treatment of Headaches: Focus on Non-invasive Therapies

  • Ho Tin Wong
  • Fayyaz AhmedEmail author
Chapter
Part of the Headache book series (HEAD)

Abstract

Primary headaches are a common indication for review in neurology clinics. Migraines, tension-type headaches and trigeminal-autonomic cephalalgia (TAC) are the most common primary headache disorders. Migraines can cause significant functional disability and cluster headaches (the commonest TAC) are one of the worst pains known to mankind. Pharmacological treatment has been the standard for both abortive and prophylactic intervention for many years, but there are patients who are refractory to medical therapy and there are others who cannot take such medications because of co-morbidities or cannot tolerate the side effects.

References

  1. 1.
    NICE. NICE. How NICE measures value for money in relation to public health interventions. 2013. www.nice.org.uk/Media/Default/guidance/LGB10-Briefing-20150126.pdf
  2. 2.
    Bruggenjurgen B, Baker T, Bhogal R, Ahmed F. Cost impact of an non-invasive, portable device for patient self-administration of chronic migraine in a UK National Health Service setting. Springerplus. 2016;5:1249.CrossRefGoogle Scholar
  3. 3.
    Morris J, Straube A, Diener H-C, Ahmed F, Silver N, Walker S, et al. Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache. J Headache Pain. 2016;17(1):43.CrossRefGoogle Scholar
  4. 4.
    Dodick DW, Turkel CC, Degryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT Clinical Program. Headache. 2010;50(6):921–36.CrossRefGoogle Scholar
  5. 5.
    NICE TAG. NICE. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Technology appraisal guidance [TA260]. 2012. https://www.nice.org.uk/guidance/ta260/resources/botulinum-toxin-typea-for-the-prevention-of-headaches-in-adults-with-chronic-migraine-pdf-82600545273541
  6. 6.
    Bhola R, Kinsella E, et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015;16:535.Google Scholar
  7. 7.
    Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373–80.CrossRefGoogle Scholar
  8. 8.
    Starling AJ, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018;38(6):1038–48. https://doi.org/10.1177/0333102418762525.CrossRefGoogle Scholar
  9. 9.
    Brighina F, Piazza A, Vitello G, Aloisio A, Palermo A, Daniele O, Fierro B. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J Neurol Sci. 2004;227(1):67–71.CrossRefGoogle Scholar
  10. 10.
    Teepker M, Hötzel J, Timmesfeld N, Reis J, Mylius V, Haag A, et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia. 2010;30(2):137–44.CrossRefGoogle Scholar
  11. 11.
    Misra UK, Kalita J, Bhoi SK. High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study. J Neurol. 2013;260(11):2793–801.CrossRefGoogle Scholar
  12. 12.
    Conforto AB, Amaro E Jr, et al. Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine. Cephalalgia. 2014;34:464–72.CrossRefGoogle Scholar
  13. 13.
    Kalita J, Laskar S, et al. Efficacy of single versus three sessions of high rate repetitive transcranial magnetic stimulation in chronic migraine and tension-type headache. J Neurol. 2016;263:2238–46.CrossRefGoogle Scholar
  14. 14.
    Shehata HS, Esmail E-J, et al. Repetitive transcranial magnetic stimulation versus botulinum toxin injection in chronic migraine prophylaxis: a pilot randomized trial. J Pain Res. 2016;9:771–7.CrossRefGoogle Scholar
  15. 15.
    Silberstein S, Calhoun A, Lipton R, Grosberg B, Cady R, Dorlas S, et al. Chronic migraine headache prevention with noninvastive vagus nerve stimulation. The EVENT study. Neurology. 2016;87:529–38.CrossRefGoogle Scholar
  16. 16.
    Gaul C, Magis D, Liebler E, Straube A. Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study. J Headache Pain. 2017;18(1):22.CrossRefGoogle Scholar
  17. 17.
    Nesbitt A, Marin J, Tompkins E, Ruttledge M, Goadsby P. Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment. Neurology. 2015;84:1249–53.CrossRefGoogle Scholar
  18. 18.
    Gaul C, Diener H-C, Silver N, Magis D, Reuter U, Andersson A, et al. Non-invasive vagus nerve stimulation for PREVention and acute treatment of chronic cluster headache (PREVA): a randomised controlled study. Cephalalgia. 2016;36(6):534–46.CrossRefGoogle Scholar
  19. 19.
    Silberstein S, Mechtler L, Kudrow D, Calhoun A, McClure C, Sapper J, et al. Non-invasive vagus nerve stimulation for the Acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache. 2016;56:1317–32.CrossRefGoogle Scholar
  20. 20.
    Goadsby P, de Coo I, Silver N, Tyagi A, Ahmed F, Gaul C, et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a randomized, double-blind, sham-controlled ACT2 study. Cephalalgia. 2018;38(5):959–69.CrossRefGoogle Scholar
  21. 21.
    Goadsby P, Grosberg B, Mauskop A, Cady P, Simmons K. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia. 2014;34(12):986–93.CrossRefGoogle Scholar
  22. 22.
    Kinfe T, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon B, Vatter H. Cervical non-invasive vagus nerve stimulation (nVNS) for preventative and acute treatment of episodic and chronic migrain and migraine-associated sleep disturbance: preliminary findings from a prospective observational cohort study. J Headache Pain. 2015;16:101.CrossRefGoogle Scholar
  23. 23.
    Barbanti P, Grazzi L, Egeo G, Padovan A, Liebler E, Bussone G. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open label study. J Headache Pain. 2015;16:61.CrossRefGoogle Scholar
  24. 24.
    Straube A, Ellrich J, Eren O, Blum B, Ruscheweyh R. Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial. J Headache Pain. 2015;16(1):63.CrossRefGoogle Scholar
  25. 25.
    Grazzi L, Egeo G, Calhoun AH, McClure C, Liebler E, Barbanti P. Non-invasive Vagus nerve stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. J Headache Pain. 2016;17(1):91.CrossRefGoogle Scholar
  26. 26.
    Schoenen J, Vandermissen B, Jeangette S, Herroelen L, Vandenheede M, Gerald P, Magis D. Migraine prevention with a supraorbital transcutaenous stimulator: a randomized controlled trial. Neurology. 2013;80:697–704.CrossRefGoogle Scholar
  27. 27.
    Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14(1):95.CrossRefGoogle Scholar
  28. 28.
    Di Fiore P, Bussone G, Galli A, Didier H, Peccarisi C, D’Amico D, Frediani F. Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open label preliminary trial. Neurol Sci. 2017;38:201–6.CrossRefGoogle Scholar
  29. 29.
    Russo A, Tessitore A, Conte F, Marcuccio L, Giordano A, Tedeschi G. Transcutaneous supraorbital neurostimulation in ‘de novo’ patients with migraine without aura: the first Italian experience. J Headache Pain. 2015;16:69.CrossRefGoogle Scholar
  30. 30.
    Vikelis M, Dermitzakis E, Spingos K, Vasiliadis G, Vlachos G, Kararizou E. Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study. BMC Neurol. 2017;17:97.CrossRefGoogle Scholar
  31. 31.
    Riederer F, Penning S, Schoenen J. Transcutaneous supraorbital nerve stimulation (t-SNS) with the Cefaly device for migraine prevention: a review of the available data. Pain Therapy. 2015;4:135–47.CrossRefGoogle Scholar
  32. 32.
    Miller S, Sinclair A, Davies B, Matharu M. Neurostimulation in the treatment of primary headaches. Pract Neurol. 2016;16:362–75.CrossRefGoogle Scholar
  33. 33.
    Bussone G, Diener H-C, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract. 2005;59(8):961–8.CrossRefGoogle Scholar
  34. 34.
    Mulleners W, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia. 2008;28(6):585–97.CrossRefGoogle Scholar
  35. 35.
    Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;2:CD003225. https://doi.org/10.1002/14651858.CD003225.pub2.

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of NeurosciencesHull York Medical SchoolHullUK

Personalised recommendations